Wall Street analysts forecast that Henry Schein (HSIC) will report quarterly earnings of $0.99 per share in its upcoming release, pointing to a year-over-year decline of 18.2%. It is anticipated that revenues will amount to $3.23 billion, exhibiting an increase of 5.5% compared to the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective. Bearing this in mind, let's now explore the average estimates of specific Henry Schein metrics that are commonly monitored and projected by Wall Street analysts. The average prediction of analysts places 'Net Sales- Healthcare Distribution - Global' at $3.03 billion. The estimate indicates a year-over-year change of +5.6%. Analysts expect 'Net Sales- Technology and value-added services- Global' to come in at $213.81 million. The estimate indicates a change of +11.9% from the prior-year quarter. The collective assessment of analysts points to an estimated 'Net Sales- Healthcare Distribution- Dental- Global' of $1.98 billion. The estimate indicates a change of +4.4% from the prior-year quarter. The combined assessment of analysts suggests that 'Net Sales- Healthcare Distribution- Medical- Global' will likely reach $1.05 billion. The estimate indicates a year-over-year change of +7.8%. According to the collective judgment of analysts, 'Net Sales- Healthcare Distribution- International' should come in at $848.12 million. The estimate points to a change of +9.6% from the year-ago quarter. Analysts' assessment points toward 'Dental- North America' reaching $1.17 billion. The estimate suggests a change of +2% year over year. The consensus among analysts is that 'Dental- International' will reach $819.20 million. The estimate points to a change of +8.7% from the year-ago quarter. Analysts predict that the 'Medical- North America' will reach $996.08 million. The estimate indicates a change of +4.7% from the prior-year quarter. It is projected by analysts that the 'Medical- International' will reach $28.92 million. The estimate suggests a change of +44.6% year over year. Analysts forecast 'Technology and value-added services- North America' to reach $185.73 million. The estimate indicates a year-over-year change of +11.9%. The consensus estimate for 'Technology and value-added services- International' stands at $27.43 million. The estimate points to a change of +9.7% from the year-ago quarter. Based on the collective assessment of analysts, 'Total Health Care Distribution- North America' should arrive at $2.16 billion. The estimate suggests a change of +3.2% year over year. View all Key Company Metrics for Henry Schein here>>> Henry Schein shares have witnessed a change of -6.4% in the past month, in contrast to the Zacks S&P 500 composite's -4.2% move. With a Zacks Rank #3 (Hold), HSIC is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Henry Schein, Inc. (HSIC):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Henry Schein (HSIC) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...